State-subsidised restaurants to offer nutritious food to deprived households
The restaurants, to open in the summer of next year, will provide 'universal access' to nutritious and sustainably-produced food in social settings, and particularly meet the needs of deprived households with children, Science and Technology Secretary Peter Kyle said.
They are one of six newly announced projects that will receive £8.5 million in Government funding to tackle food inequality, including a mapping tool to direct a mobile greengrocer to visit areas of Liverpool where social housing residents have limited access to fresh fruit and vegetables.
Exciting news! 🎉
The @QueenGreensBus is launching a new route from today, bringing affordable #GoodFood to new stops across #Liverpool and #Knowsley.
Food can be bought using cash, card, @NHSHealthyStart cards and @AlexRoseCharity vouchers.
Timetable👉https://t.co/k3iWxBAjdw pic.twitter.com/H9h97HueF4
— Queen of Greens (@QueenGreensBus) September 9, 2024
Under the Liverpool initiative, expected to begin in spring of next year, research will direct the 'Queen of Greens' bus, which has delivered fresh fruit and vegetables to communities across Liverpool and Knowsley since 2022, to residents in social housing who may find it harder to access healthier options in their neighbourhoods, Mr Kyle said.
In some areas, residents will receive vouchers to buy fruit and vegetables from the bus.
Researchers will measure how the diet and health of recipients change as a result of the initiative in order to predict the effect of it being rolled out across the country.
It follows the launch of the Government's 10-Year Health Plan, which last week included the announcement that supermarkets could be fined if they do not sell healthier food.
Other projects will assess the role of community food markets in areas of Glasgow with limited access to grocery stores, known as 'food deserts', surveying food pantry users to find out about other activities and support they would like to see on offer, such as cooking sessions or recipe boxes, and improving the nutritional content and take-up of free school meals.
Mr Kyle said: 'No one in this country should be left unable to access the healthy food they need – which is why interventions like the Queen of Greens are so important – and measuring their impact is so vital.
'These projects will draw on the power of research to actively explore the best ways to get healthy food into the mouths of those who need it, potentially having a transformational effect on people's lives, and fulfilling the missions set in our Plan for Change.'
Lucy Antal, director of Alchemic Kitchen CIC (Community Interest Company), who runs the Queen of Greens, said: 'We are very much looking forward to working on this new research project with all the team assembled by the University of Liverpool.
'It will be a great opportunity to trial an expansion into supporting social housing tenants to access fresh produce, and to have the health and social impact of this intervention measured and assessed. The Queen of Greens is for everyone, and the data produced will help support our future activity.'
Professor Alison Park, deputy executive chairwoman of the Economic and Social Research Council (ESRC), part of UK Research and Innovation (UKRI), said: 'Everyone should have access to healthy, nutritious food but we know the number of food insecure households across the UK is increasing.
'These innovative projects from across the UK – from Wales to Dundee, Nottingham to the Isle of Wight – will go a long way in helping us understand how to tackle food inequalities and what interventions really make a difference.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Missed chances to save daughter found dead with mum
A disabled teenage girl could have been saved if an ambulance had attended her dying mother's 999 call - months before they were both found dead in their home, a coroner has concluded. Nottingham Coroner's Court heard Alphonsine Djiako Leuga, 47, and 18-year-old Loraine Choulla had been dead for some time before they were found on 21 May 2024 in a house in Radford. It was believed Alphonsine died first, in February, while Loraine - who had Down's syndrome and depended "entirely" on her mum - died of malnutrition and dehydration weeks later. On Friday, assistant coroner Amanda Bewley said authorities "missed opportunities" to escalate concerns around the pair. An inquest into their deaths, which started on Monday, heard Alphonsine had called for an ambulance on 2 February saying she was cold and could not move, but nobody attended. Pathologist Dr Stuart Hamilton said he could "not rule out" that Alphonsine might have died on 2 February, which is when she called 999. 'Please come, please' Alphonsine had been admitted to City Hospital on 26 January with a lower respiratory tract infection and needed blood transfusions due to low iron levels. The inquest heard despite the hospital wanting her to stay, she was "discharged pragmatically" on 28 January to return to her daughter. On 2 February, Alphonsine called 999 asking for an ambulance, the inquest heard. She told a call handler she needed help for herself and her daughter. "I feel cold and I can't move," she told the call handler. In a transcript read out at the inquest, the call handler asked several times what language Alphonsine spoke and whether she needed an interpreter. Despite not responding to those questions, she gave her address and asked again for an ambulance. "Would you send an ambulance? Please come, please," were the last words she said on the phone before the call ended. Keeley Sheldon, director of quality at East Midlands Ambulance Service, said the service "fully accept" the coroner's findings. She said: "I am truly sorry that we did not respond as we should have to Alphonsine Djiako Leuga and Lorraine Choulla. Our deepest condolences remain with their family. "After our internal investigation, we made changes to our policies, procedures and training to ensure this does not happen in future." If you have been affected by any of the issues raised in this story, support is available via the BBC Action Line Follow BBC Nottingham on Facebook, on X, or on Instagram. Send your story ideas to eastmidsnews@ or via WhatsApp on 0808 100 2210. More on this story Disabled daughter 'alone for weeks after mum died' Mum found dead with daughter refused support Mum and daughter found dead months after 999 plea Review after 'shocking' deaths of mum and daughter Related internet links HM Courts & Tribunals Service
Yahoo
2 days ago
- Yahoo
COVID-19 Made Our Brains Age Faster
Credit - Yuichiro Chino—Getty Images COVID-19 is leaving all kinds of legacies on our health, both on our bodies and our brains. In a study published July 22 in Nature Communications, researchers report that living through the pandemic aged our brains—whether or not you were infected with COVID-19. To investigate COVID-19's impact on the brain, researchers looked at brain scans from 1,000 people during and before the pandemic. They compared these to brain scans from other people taken during "normal" times as a model for typical brain aging. Led by Ali-Reza Mohammadi-Nejad from the University of Nottingham School of Medicine in the U.K., the researchers looked at measures like brain function, gray and white matter volume, a person's cognitive skills, and their chronological age. Gray matter is critical for memory, emotions, and movement, while white matter is essential for helping nerves transmit electrical signals. The pandemic-era brains aged about 5.5 months faster compared to the brains of those studied before the pandemic. The accelerated aging was documented in people who had COVID-19 infections as well as those who didn't, which strongly suggests that pandemic-related factors other than biological or virus-driven ones—like high stress—were also at work. In fact, the changes in gray and white matter were similar in people who were and were not infected. 'This finding was interesting and rather unexpected,' says Mohammadi-Nejad. Other studies have already shown that the COVID-19 virus can change the brain for the worse, but "we found that participants who simply lived through the pandemic period, regardless of infection, also showed signs of slightly accelerated brain aging. This highlights that the broader experience of the pandemic—including disruptions to daily life, stress, reduced social interactions, reduced activity, etc.,—may have had a measurable impact on brain health.' Read More: What to Know About the New COVID-19 Variant XFG The impact of the pandemic seemed to be greater in certain groups—notably men, the elderly, and people with more compromised health, lower educational status and income, or unstable housing. People with less stable employment had an average of five months of additional brain aging compared to those with higher employment status, while poorer health added about four months of increased brain age compared to better health. However, only people infected with COVID-19 showed drops in cognitive skills. But the fact that those who weren't infected during the pandemic also showed accelerated aging reflects the need to acknowledge the broader health effects of the pandemic beyond the obvious physical metrics on which doctors tend to focus. 'Brain health can be influenced by everyday life activities, and major societal disruptions—like those experienced during the pandemic—can leave a mark even in healthy individuals,' Mohammadi-Nejad says. 'This adds to our understanding of public health by reinforcing the importance of considering mental, cognitive, and social well-being alongside traditional physical health indicators during future crisis-response planning.' While the study did not explore specific ways to address brain aging, he says that strategies known to maintain brain health, such as a healthy diet, exercise, adequate sleep, and social and cognitive interactions are important, especially in the context of stressful circumstances such as a pandemic. 'Whether these can reverse the specific changes we observed remains to be studied,' he says. Contact us at letters@ Solve the daily Crossword
Medscape
3 days ago
- Medscape
Most Promising OTC Products for Depression Flagged
Among over-the-counter (OTC) products for depression, St. John's wort, saffron, probiotics, and vitamin D have the strongest evidence of efficacy, new research showed. However, folic acid and lavender also show promise and should be prioritized in future research, the investigators noted. Rachael Frost, PhD As more patients turn to OTC products to manage depressive symptoms, it's important to answer questions about the state of the related research, study investigator Rachael Frost, PhD, Senior Lecturer in Health and Social Care, School of Public and Allied Health, Liverpool John Moores University, Liverpool, England, who is herbal practitioner, told Medscape Medical News . Frost said her team aimed to map the current evidence base for OTC products for depression — asking whether research has focused too narrowly on a few supplements, whether other promising options are being overlooked, and how future studies and consumer guidance could be better directed. The findings were published online on July 15 in Frontiers in Pharmacology . Mapping the Research The prevalence of major depressive disorder (MDD) ranges from 2% to 21%, depending on the country and the measures used, and rates continue to rise — prompting some experts to describe depression as a growing epidemic. Many patients are reluctant to take antidepressants and face long wait times for psychological therapies, said Frost. 'There's a strong drive for people to self-manage, particularly if they have mild or moderate symptoms of depression,' she noted. Part of a larger project summarizing existing evidence on OTC products — including herbal medicinal products (HMPs), vitamins and minerals, and homeopathic preparations — for depression, anxiety, and insomnia, the goal of the current review was to 'map' the full research landscape on OTC products for depression in adults aged 18-60 and identify gaps where further study is needed, said Frost. The review included 209 trials assessing 64 different products. Most studies were conducted in Iran, followed by Germany, the US, Australia, the UK, and China. Double-blind designs were the most common. Sample sizes varied widely, with a median of 62 participants per study. All trials used depression rating scales as either primary or secondary outcomes. The most frequently used were the Hamilton Depression Rating Scale, the Montgomery-Aberg Depression Rating Scale, and the Clinical Global Impression Scale. Dietary supplements were evaluated in 114 trials, HMPs in 94 trials, and one trial — outside these categories — investigated aspirin. Evidence Gaps In the HMP category, most studies focused on products in capsule form. Frost found this somewhat surprising given the popularity, affordability, and ease of incorporating herbal teas into daily life. She suggested the lack of research on teas may be due to practical challenges — such as the difficulty of creating a placebo tea for controlled trials. Notably, none of the studies evaluated homeopathic products for depression. 'Homeopathic trials just focused on well–being, rather than looking at people who had symptoms or a diagnosis of depression,'saidFrost. Few studies examined multivitamins, which can be challenging to evaluate due to varying combinations of vitamins, minerals, and sometimes added herbal extracts or probiotics, Frost explained. Dietary supplements were more often compared to placebo (86%) than HMPs (67%), whereas HMPs were more frequently compared to prescription drugs (32%) than dietary supplements (5%). Additionally, supplements were more likely to be tested as adjuncts to other depression treatments, most commonly antidepressants — compared to HMPs. Very few studies evaluated OTC products vs psychotherapy. This, said Frost, is despite psychological therapies being 'quite popular' and often a first–line treatment for depression. 'Whether psychological therapies are better than OTC products or if there would be additive effects if people take both at the same time, is a question that needs answering,' she said. Products With Potential Products supported by evidence from more than 10 trials included St. John's wort, saffron, probiotics, and vitamin D. Within these categories, a variety of products, extracts, and dosages were tested. Most studies on St. John's wort favored its use compared with placebo and showed effects comparable to or better than prescription antidepressants. While the evidence for St. John's wort is strong, caution is advised due to potential interactions with antidepressants, contraceptive pills, and other medications, said Frost. Saffron products also showed generally positive effects compared with placebo. When evaluated alongside antidepressants, saffron demonstrated similar benefits and could be a promising new option to recommend, said Frost. Results for both probiotics and vitamin D favored the intervention compared with placebo. 'Given that probiotics and vitamin D also might provide benefits for things like the gut, bone health, and immunity, they are probably worth recommending,' Frost noted. Potential mechanisms by which these OTC products may alleviate depressive symptoms include reducing inflammation, mitigating oxidative stress, modulating the microbiota-gut-brain axis, suppressing hyperactivity of the hypothalamic-pituitary-adrenal axis, and regulating neurotransmitter activity. The review included several trials on omega-3 supplements, most comparing them to placebo. Frost noted that these studies were more likely to report null findings, indicating that omega-3 may not be a strong recommendation for depression. Among products with emerging evidence (two to nine trials), the review identified folic acid, lavender, zinc, tryptophan, rhodiola, and lemon balm as the most promising. Bitter orange, Persian lavender (Nepeta menthoides), and chamomile each showed positive results in two trials. These promising products, Frost said, warrant further evaluation to better understand their potential benefits. While some emerging OTC products show promise, Frost cautions that their effectiveness is not guaranteed. She stresses the importance of doctors having open, honest discussions with patients to ensure any supplements do not interfere with existing health conditions or medications. The study on aspirin showed no evidence of efficacy for depression. Many trials lacked sufficient safety data; however, among those that reported safety outcomes, most products demonstrated a favorable safety profile, Frost noted. Experts Weigh In Commenting on the research for Medscape Medical News , Jonathan Burgess, MD, clinical assistant professor at Lifestyle Psychiatry Clinic, Stanford University, in Stanford, California, said the review gives him 'quite a bit of homework,' as he plans to examine several of the original studies. However, he pointed out that the review did not differentiate between eicosapentaenoic acid (EPA)-predominant and docosahexaenoic acid-predominant omega-3 formulations. Contrary to the review's suggestion that omega-3s are ineffective for depression, Burgess noted that multiple meta-analyses have shown that EPA-predominant formulas are convincingly effective for depression. He said that beyond advising a healthy diet, regular exercise, and good sleep hygiene, EPA-predominant omega-3s, St. John's wort, saffron, and probiotics are his 'go-to's' for patients with depression who want to try OTC treatments. Burgess agreed that lavender and folate show considerable promise but cautioned that, like any effective treatment, they can have side effects. He cited cases where patients overused lavender and experienced suicidal thoughts, warned that excessive zinc intake can disrupt copper balance, and highlighted the risk of serotonin syndrome—a potentially life-threatening condition — in patients taking tryptophan alongside St. John's wort. Also commenting for Medscape Medical News was David Mischoulon, MD, PhD, director of the Depression Clinical and Research Program at Massachusetts General Hospital and professor of Psychiatry at Harvard Medical School, both in Boston, who has extensively researched natural remedies. He said the review offers a useful snapshot of the current state of the field and aligns with his overall understanding of the evidence base. However, he questioned why the review included so few studies on S-adenosyl-methionine (SAMe), a compound involved in the synthesis of neurotransmitters such as serotonin, dopamine, and norepinephrine. The review cited only two parallel randomized controlled trials on SAMe, one of which he coauthored. 'I'm surprised because it's one of the better studied natural products. The review seems to underestimate how much has been done with regard to that particular product,' said Mischoulon. Mischoulon said he is 'a lot more comfortable' recommending SAMe for patients with depression than many other OTC products, largely due to its strong safety profile. Aside from occasional nausea or indigestion at higher doses, SAMe is generally well tolerated. Unlike St. John's wort — which can interact with immunosuppressants, antiretrovirals, cancer therapies, antidepressants, and hormonal contraceptives — SAMe does not interact with other medications, he noted. In addition to SAMe, Mischoulon also considers omega-3 supplements a viable OTC option for depression. However, he emphasized the importance of directing future research toward emerging products. He noted that well-studied options like St. John's wort and omega-3s have already been thoroughly reviewed and suggested that greater attention should be given to lesser-known supplements such as lavender and folic acid.
